SCPH 8-K: Amendment 1 to Supply Agreement with West Pharmaceutical

Rhea-AI Filing Summary

scPharmaceuticals Inc. filed an 8-K reporting an amendment to a supply agreement: Amendment 1 to the Supply Agreement dated August 20, 2025 between West Pharmaceutical Services, Inc. and the registrant. The filing includes a cover page interactive data file embedded in the inline XBRL document and is signed by John H. Tucker, President and Chief Executive Officer of scPharmaceuticals Inc.

The filing identifies the amendment document and the parties but does not provide the amendment's financial terms, operational changes, or material effects on the company within the provided excerpt.

Positive

• Disclosed an amendment to an existing supply agreement (Amendment 1 dated August 20, 2025) with West Pharmaceutical Services, Inc.
• Included an interactive data exhibit (inline XBRL cover page), indicating use of structured filing formats
• Signed by the CEO, showing authorized company certification of the filing

Negative

• No amendment terms disclosed in the provided excerpt — no pricing, duration, obligations, or material effect described
• Insufficient detail to assess materiality or financial/operational impact from the amendment

Insights

Corporate Governance Expert

TL;DR: Company disclosed a contractual amendment with a supplier but provided no terms or material impact details.

The 8-K excerpt clearly notifies investors that an amendment to an existing supply agreement was executed on August 20, 2025, with West Pharmaceutical Services, Inc., and that the registrant filed an interactive data exhibit. From a governance and disclosure perspective, timely filing of an 8-K for a material contract amendment is appropriate. However, the excerpt lacks specifics on amended obligations, pricing, duration, termination rights, or guarantees, which prevents assessment of governance implications or potential effects on operations and cash flow.

Securities/Compliance Analyst

TL;DR: The filing documents a supply-agreement amendment but omits substantive terms needed to judge investor impact.

As presented, the company complied with procedural reporting by identifying the amendment and including an interactive data file. The absence of disclosed financial or operational terms in the excerpt means investors cannot evaluate whether the amendment is material. For compliance review, follow-up disclosure or attached exhibits containing the amendment text would be necessary to determine reporting sufficiency and any required financial statement effects.

false 0001604950 0001604950 2025-08-20 2025-08-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 20, 2025

scPharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38293		46-5184075
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

25 Mall Road, Suite 203 Burlington, Massachusetts		01803
(Address of principal executive offices)		(Zip Code)

(617) 517-0730

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		SCPH		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On August 20, 2025, scPharmaceuticals Inc. (the “Company”) entered into an amendment (the “Amendment”) to that certain Supply Agreement, dated August 15, 2020, by and between the Company and West Pharmaceutical Services, Inc. (“West”), pursuant to which the Company agreed to purchase the SmartDose® drug delivery system developed by West (the “Agreement”).

The Amendment provides for, among other things: (i) that the term of the Agreement will continue in effect until December 31, 2027 and does not automatically extend or automatically renew and (ii) upon election of termination of the Agreement by either party, that the Company will be responsible for payment to West for any costs incurred and purchase orders accepted through the date of termination of the Agreement.

The foregoing description of the Amendment is a summary, and is qualified in its entirety by reference to such document, which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1*		Amendment 1 to the Supply Agreement, dated August 20, 2025, by and between West Pharmaceutical Services, Inc. and the Registrant
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

* Portions of this exhibit (indicated by asterisks) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				SCPHARMACEUTICALS INC.
Date: August 25, 2025				By:		/s/ John H. Tucker
				Name:		John H. Tucker
				Title:		President and Chief Executive Officer

FAQ

What did scPharmaceuticals (SCPH) report in this 8-K?

The company reported Amendment 1 to the Supply Agreement dated August 20, 2025 between scPharmaceuticals and West Pharmaceutical Services, Inc., and filed an inline XBRL cover page exhibit.

Does the filing disclose financial terms of the amendment?

No. The provided excerpt does not include financial terms, pricing, duration, or other operational details of the amendment.

Who signed the 8-K for scPharmaceuticals?

The filing excerpt is signed by John H. Tucker, identified as President and Chief Executive Officer of scPharmaceuticals Inc.

When was the amendment dated?

The amendment is dated August 20, 2025, and the filing excerpt references a company date of August 25, 2025.

Is this amendment automatically material to investors?

The excerpt does not provide enough information to determine materiality; no terms or impacts are disclosed so materiality cannot be assessed from this content alone.